17,261 trials
Breast Cancer · Precancerous Condition
Primary: Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy — 1.00; -0.05 µM/mM creatinine
Hepatitis C, Chronic
Primary: Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1 — 43 Participants
Total Hip Arthroplasty · Muscle Injury
Primary: Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength. — 31.17; 20.36; 5.43…
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
Kidney Cancer · Lung Cancer · Metastatic Cancer
Primary: Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry — 1; 3; 2 Participants
Indolent or Intermediate Grade B-cell Malignancy
Primary: Incidence of Grade III and IV Hypersensitivity Reactions — 0 percentage of patients
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I) — NA
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Number of Participants With Overall Response (OR) — 15; 4 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Cell Carcinoma · Endometrial Clear Cell Carcinoma
Primary: Objective Clinical Response Rate — 13.8; 4.0 percentage of patients with response
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants
Low Back Pain · Pain
Primary: Change in Numeric Rating Scale (NRS-11) — -2.47; -1.55 units on a scale
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Primary: Number of Patients With No Visible Implants in the Study Eye — 14; 37; 26; 35 Patients
Recurrent Neuroblastoma
Primary: Number of Patients With Unacceptable Dose Limiting Toxicities (DLTs) — 1; 2; 9; 18 participants
Peanut Allergy
Primary: Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg) — 13 participants
Plaque Psoriasis
Primary: Number of Patients With Adverse Events — 4; 5; 7; 6 participants